Related Experiment Video
Updated: Mar 21, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary
Igor-Wolfgang Blau1, Niall Conlon2, Robert Petermann3
1a Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie , Charité - Universitätsmedizin , Berlin , Germany.
Abstract:
The number of patients with secondary immune deficiencies (SID) is on the rise, mostly since the arrival on the market of novel targeted therapies that have increased the survival rates of patients with hematological malignancies. The recent changes in the SID landscape have brought with them new and diverse medical needs that treatments for SID management should strive to meet. In this special report, we study the opportunities provided by facilitated subcutaneous immunoglobulin administration (fSCIg) to treat patients for whom the conventional routes (intravenous and subcutaneous) are sub-optimal. Experts in the treatment of SID describe real-life cases from their daily practice, in which fSCIg has led to reducing the burden of treatment and increasing the treatment satisfaction.
Related Concept Videos
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Immunofluorescence Microscopy
Humoral Immune Responses
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

